Sirtex Medical Ltd fell as much as 13.3% this morning to $14.74 per share. This morning, SRX revealed the results of their 459 patient SARAH clinical study.
Expect this little research experiment of ours to be the norm. Over the next few years you’ll find the use of cannabis widespread.
We’re keeping a close eye on this ASX marijuana play. The only Aussie pot firm awarded a license to grow commercial quantities of marijuana on Canadian soil.
Luckily, we live in an era when we can watch the unravelling of marijuana prohibition in the Western world, and see the benefits that it brings.
We’re at the start-point of a new medical age, when cannabis-derived treatments could halt cancer, cure Arthritis, stop Parkinson’s in its tracks, reduce severe epileptic seizures, and much, much more.
What really makes a car company great? Is it the profit they can make per car? Is it the amount of profit the company can make overall? Or is it innovation?
Clinuvel Pharmaceuticals Ltd [ASX:CUV] is a small biotech company developing drugs to treat a range of skin disorders. The stock climbed 5.35% on Wednesday to a high of $7.28 per share.
Within hours or days of receiving it, the information junkie is on to other things. The new product goes up on the shelf with the old products.
If you want your portfolio to have some potential big winners, you have to invest at the edge of understanding. That’s where the potential lies.
Mesoblast Ltd [ASX:MSB] climbed 6.5% this morning, to a high of $2.60 per share. The rally added as much as $70 million to the biotech’s market cap.